Cargando…

Smart Wearables for Cardiac Monitoring—Real-World Use beyond Atrial Fibrillation

The possibilities and implementation of wearable cardiac monitoring beyond atrial fibrillation are increasing continuously. This review focuses on the real-world use and evolution of these devices for other arrhythmias, cardiovascular diseases and some of their risk factors beyond atrial fibrillatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Duncker, David, Ding, Wern Yew, Etheridge, Susan, Noseworthy, Peter A., Veltmann, Christian, Yao, Xiaoxi, Bunch, T. Jared, Gupta, Dhiraj
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038592/ https://www.ncbi.nlm.nih.gov/pubmed/33916371 http://dx.doi.org/10.3390/s21072539

Ejemplares similares

Ablation index-guided 50W radiofrequency ablation for left atrial posterior wall isolation in atrial fibrillation
por: Ding, Wern Yew, et al.
Publicado: (2022)

Stroke and Bleeding Risk Assessments in Patients With Atrial Fibrillation: Concepts and Controversies
por: Ding, Wern Yew, et al.
Publicado: (2020)

Relationship between Renal Function, Fibrin Clot Properties and Lipoproteins in Anticoagulated Patients with Atrial Fibrillation
por: Ding, Wern Yew, et al.
Publicado: (2022)

Role of the Wearable Defibrillator in Newly Diagnosed Heart Failure
por: Duncker, David, et al.
Publicado: (2018)

Percutaneous Left Atrial Appendage Occlusion: A View From the UK
por: Ding, Wern Yew, et al.
Publicado: (2020)

Short‐Term Outcomes in Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: How Important Is Ethnicity?
por: Ding, Wern Yew, et al.
Publicado: (2019)

Residual Stroke Risk in Atrial Fibrillation
por: Ding, Wern Yew
Publicado: (2021)

Short-Term Apixaban for Documented Left Atrial Appendage Thrombus in High-Risk Atrial Fibrillation Patients Undergoing Left Atrial Appendage Occlusion
por: Ding, Wern Yew, et al.
Publicado: (2020)

Relationship between temporal rhythm-based classification of atrial fibrillation and stroke: real-world vs. clinical trial
por: Ding, Wern Yew, et al.
Publicado: (2022)

Atrial fibrillation ablation performed in the developing world: A description of the first atrial fibrillation ablation performed in Cambodia
por: Sundaram, Sri, et al.
Publicado: (2015)

Outcomes of left atrial appendage occlusion vs. non-vitamin K antagonist oral anticoagulants in atrial fibrillation
por: Ding, Wern Yew, et al.
Publicado: (2022)

Impact of early ablation of atrial fibrillation on long-term outcomes: results from phase II/III of the GLORIA-AF registry
por: Ding, Wern Yew, et al.
Publicado: (2022)

Is Atrial Fibrillation Management as Simple as ABC?
por: Yao, Xiaoxi, et al.
Publicado: (2020)

Incidence and Risk Factors for Residual Adverse Events Despite Anticoagulation in Atrial Fibrillation: Results From Phase II/III of the GLORIA‐AF Registry
por: Ding, Wern Yew, et al.
Publicado: (2022)

Atrial Fibrillation in Patients With Cardiomyopathy: Prevalence and Clinical Outcomes From Real‐World Data
por: Buckley, Benjamin J. R., et al.
Publicado: (2021)

Feasibility of weight loss in obese atrial fibrillation patients attending a specialist arrhythmia clinic and its impact on ablation outcomes
por: Yew Ding, Wern, et al.
Publicado: (2020)

On-treatment follow-up in real-world studies of direct oral anticoagulants in atrial fibrillation: Association with treatment effects
por: Hutto, David, et al.
Publicado: (2022)

Relationship between lipoproteins, thrombosis, and atrial fibrillation
por: Ding, Wern Yew, et al.
Publicado: (2021)

Characterizing Real-World Implementation of Consumer Wearables for the Detection of Undiagnosed Atrial Fibrillation in Clinical Practice: Targeted Literature Review
por: Simonson, Julie K, et al.
Publicado: (2023)

Avoiding Untimely Implantable Cardioverter/Defibrillator Implantation by Intensified Heart Failure Therapy Optimization Supported by the Wearable Cardioverter/Defibrillator—The PROLONG Study
por: Duncker, David, et al.
Publicado: (2017)

Smart detection of atrial fibrillation(†)
por: Krivoshei, Lian, et al.
Publicado: (2017)

Contribution of atrial myofiber architecture to atrial fibrillation
por: Kamali, Roya, et al.
Publicado: (2023)

Anticoagulation for Stroke Prevention in Older Adults with Atrial Fibrillation and Comorbidity: Current Evidence and Treatment Challenges
por: Sabbag, Avi, et al.
Publicado: (2018)

Usage of the wearable cardioverter-defibrillator during pregnancy
por: Olic, J.-Jacqueline, et al.
Publicado: (2022)

Diagnostic accuracy of smart gadgets/wearable devices in detecting atrial fibrillation in primary prevention: a meta-analysis
por: Vetta, G, et al.
Publicado: (2023)

Defining the benefit: Cardioversion of persistent atrial fibrillation
por: Nedios, Sotirios, et al.
Publicado: (2021)

Atrial Fibrillation and Dementia: Exploring the Association, Defining Risks and Improving Outcomes
por: Bunch, T Jared, et al.
Publicado: (2019)

Atrial Fibrillation Classification with Smart Wearables Using Short-Term Heart Rate Variability and Deep Convolutional Neural Networks
por: Ramesh, Jayroop, et al.
Publicado: (2021)

Adherence to the Atrial Fibrillation Better Care (ABC) pathway and the risk of major outcomes in patients with atrial fibrillation: A post-hoc analysis from the prospective GLORIA-AF Registry
por: Romiti, Giulio Francesco, et al.
Publicado: (2022)

Prediction of Residual Stroke Risk in Anticoagulated Patients with Atrial Fibrillation: mCARS
por: Ding, Wern Yew, et al.
Publicado: (2021)

Anti-cancer Drugs Associated Atrial Fibrillation—An Analysis of Real-World Pharmacovigilance Data
por: Ahmad, Javaria, et al.
Publicado: (2022)

Stroke-independent contribution of atrial fibrillation to dementia: a meta-analysis
por: Saglietto, Andrea, et al.
Publicado: (2019)

Frequent premature atrial contractions as a signalling marker of atrial cardiomyopathy, incident atrial fibrillation, and stroke
por: Farinha, José Maria, et al.
Publicado: (2022)

Patient experience of very high power short duration radiofrequency ablation for atrial fibrillation under mild conscious sedation
por: Chu, Gavin, et al.
Publicado: (2022)

Rivaroxaban Precision Dosing Strategy for Real‐World Atrial Fibrillation Patients
por: Konicki, Robyn, et al.
Publicado: (2020)

Real‐World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation
por: Lin, Shin‐Yi, et al.
Publicado: (2019)

Real-World Data of Anticoagulant Treatment in Non-valvular Atrial Fibrillation
por: Calderon, Jose Miguel, et al.
Publicado: (2022)

Survey Study of the Real‐World Outpatient Management of Postoperative Atrial Fibrillation
por: Patel, Nirav V., et al.
Publicado: (2023)

Rivaroxaban and apixaban in patients with atrial fibrillation; a real-world data
por: ASLAN, Onur, et al.
Publicado: (2022)

Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
por: Yao, Xiaoxi, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_fmqlrmhudvd3lpo5kgb8m7ihu4